Cargando…

Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives

[Image: see text] Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues. Here, we demonstrate that positron emission tomography (PET) based detection of prostate specific membrane antigen (PSMA) in prostatic tumor models using e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viola-Villegas, Nerissa Therese, Sevak, Kuntal K., Carlin, Sean D., Doran, Michael G., Evans, Henry W., Bartlett, Derek W., Wu, Anna M., Lewis, Jason S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224519/ https://www.ncbi.nlm.nih.gov/pubmed/24779727 http://dx.doi.org/10.1021/mp500164r

Ejemplares similares

Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab)
por: McKnight, Brooke N., et al.
Publicado: (2018)

(89)Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging
por: Kuda-Wedagedara, Akhila N. W., et al.
Publicado: (2017)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Histologically Confirmed Testicular Metastasis Revealed by [(89)Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
por: Rosar, Florian, et al.
Publicado: (2023)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
por: Pandit-Taskar, Neeta, et al.
Publicado: (2015)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Applying (89)Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins
por: Doran, Michael G., et al.
Publicado: (2016)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
por: Fung, Edward K., et al.
Publicado: (2016)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Development and evaluation of (89)Zr-trastuzumab for clinical applications
por: Mohammadpour-Ghazi, Fatemeh, et al.
Publicado: (2023)

Spatio-temporal biodistribution of (89)Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model
por: Sta Maria, Naomi S., et al.
Publicado: (2021)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

Annotating MYC oncogene status with (89)Zr-transferrin imaging
por: Holland, Jason P., et al.
Publicado: (2012)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

(89)Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
por: Kahts, Maryke, et al.
Publicado: (2023)

Biodistribution of Mesenchymal Stromal Cells Labeled with [(89)Zr]Zr-Oxine in Local Radiation Injuries in Laboratory Animals
por: Astrelina, Tatiana A., et al.
Publicado: (2023)

Design and preclinical evaluation of a (99m)Tc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)
por: Kampmeier, Florian, et al.
Publicado: (2014)

CD38‐Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu‐Labeled Daratumumab
por: Kang, Lei, et al.
Publicado: (2021)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores
por: Petrik, Milos, et al.
Publicado: (2015)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)

In Vivo PET Imaging of Monocytes Labeled with [(89)Zr]Zr-PLGA-NH(2) Nanoparticles in Tumor and Staphylococcus aureus Infection Models
por: Krekorian, Massis, et al.
Publicado: (2021)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_alrljaevcbefj5btibbrcqn0q8